Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.
暂无分享,去创建一个
Soma Das | Federico Innocenti | Michael L Maitland | Ravi Salgia | Richard L Schilsky | Robert Marsh | Mark J Ratain | Theodore Karrison | M. Maitland | R. Schilsky | M. Ratain | Soma Das | R. Salgia | F. Innocenti | J. Ramírez | T. Karrison | Jacqueline Ramírez | Larry K House | L. Janisch | R. Marsh | Linda Janisch | S. Undevia | Kehua Wu | Samir Undevia | Michelle Turcich | L. House | Ke-hua Wu | Michelle Turcich
[1] F. Innocenti,et al. Clinical Implementation of Germ Line Cancer Pharmacogenetic Variants During the Next‐Generation Sequencing Era , 2014, Clinical pharmacology and therapeutics.
[2] Joshua M. Stuart,et al. The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.
[3] Jan Bogaerts,et al. Designing transformative clinical trials in the cancer genome era. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] M. Baiget,et al. A genotype-directed phase I–IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer , 2011, British Journal of Cancer.
[5] Jeffrey D Sachs,et al. Expansion of cancer care and control in countries of low and middle income: a call to action , 2010, The Lancet.
[6] F. Innocenti,et al. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Z. Kmietowicz. Task force hopes to deliver affordable cancer drugs to developing countries , 2009, BMJ : British Medical Journal.
[8] R. Schilsky,et al. Translating the cancer genome into clinically useful tools and strategies , 2009, Disease Models & Mechanisms.
[9] Wei Zhang,et al. Hepatocyte nuclear factor-1 alpha is associated with UGT1A1, UGT1A9 and UGT2B7 mRNA expression in human liver , 2008, The Pharmacogenomics Journal.
[10] W. Humphreys,et al. Characterization of the UDP Glucuronosyltransferase Activity of Human Liver Microsomes Genotyped for the UGT1A1*28 Polymorphism , 2007, Drug Metabolism and Disposition.
[11] Joseph G Ibrahim,et al. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. , 2007, Journal of the National Cancer Institute.
[12] Teruhiko Yoshida,et al. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28 , 2007, Pharmacogenetics and genomics.
[13] M. Ratain,et al. The Role of SN‐38 Exposure, UGT1A1*28 Polymorphism, and Baseline Bilirubin Level in Predicting Severe Irinotecan Toxicity , 2007, Journal of clinical pharmacology.
[14] M. Ratain,et al. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. , 2006, Pharmacogenomics.
[15] Giuseppe Toffoli,et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] E. Shin,et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] E. Eisenhauer,et al. RECIST revisited: a review of validation studies on tumour assessment. , 2006, European journal of cancer.
[18] J. Meyerhardt,et al. Systemic therapy for colorectal cancer. , 2005, The New England journal of medicine.
[19] Soma Das,et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] M. Egorin. Horseshoes, hand grenades, and body-surface area-based dosing: aiming for a target. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] A. Di Rienzo,et al. Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. , 2002, Pharmacogenetics.
[22] J. Verweij,et al. Impact of body-size measures on irinotecan clearance: alternative dosing recommendations. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] R. Schilsky,et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity , 2002, The Pharmacogenomics Journal.
[24] A. Di Rienzo,et al. Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates. , 1999, Pharmacogenetics.
[25] A. Di Rienzo,et al. Phenotype‐genotype correlation of in vitro SN‐38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism , 1999, Clinical pharmacology and therapeutics.
[26] P. Hérait,et al. High dose-intensity of irinotecan administered every 3 weeks in advanced cancer patients: a feasibility study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] S. Culine,et al. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.